A Phase II study of AVN 211 in patients with schizophrenia in a condition of incomplete remission receiving stable antipsychotic therapy

Trial Profile

A Phase II study of AVN 211 in patients with schizophrenia in a condition of incomplete remission receiving stable antipsychotic therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2015

At a glance

  • Drugs AVN 211 (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jul 2015 Status changed from recruiting to completed as reported in an Avineuro pharmaceuticals media release.
    • 16 Jul 2015 Results published in an Avineuro pharmaceuticals media release.
    • 25 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top